Date published: 2026-7-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

JNK1 CRISPR/Cas9 KO Plasmid (bovine): sc-437283

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: bovine
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • JNK1 CRISPR/Cas9 Knockout (KO) Plasmid (bovine) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the JNK1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    JNK1 CRISPR/Cas9 KO Plasmid (bovine)

    sc-437283
    20 µg
    $397.00

    Overview

    JNK1 (MAPK8) is a stress-activated mitogen-activated protein kinase that integrates upstream signals from cytokines, growth factors, reactive oxygen species, and DNA damage to regulate transcriptional programs through targets such as c-Jun and other AP-1 components. In bovine cells, JNK1 contributes to control of apoptosis, inflammatory signaling, and differentiation by coordinating MAPK cascades that intersect with NF-κB, insulin signaling, and TGF-β-associated responses. JNK1 activity influences cellular outcomes including proliferation, migration, and extracellular matrix remodeling, making it relevant to models of tissue stress, metabolic dysregulation, and immune activation. Dysregulated JNK signaling has been associated broadly with inflammatory and degenerative pathologies, supporting its utility as a mechanistic node in pathway-focused research.

    JNK1 CRISPR/Cas9 KO Plasmid (bovine) is a pool of plasmids designed for targeted disruption of the gene in bovine cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish JNK1 protein expression.

    This CRISPR knockout system enables efficient generation of -deficient cell models for investigation of JNK1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting exon(s) critical for JNK1 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by JNK1 CRISPR/Cas9 KO Plasmid (bovine) and JNK1 CRISPR/Cas9 KO Plasmid (bovine2) target distinct sites within the locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by JNK1 HDR Plasmid (bovine) and JNK1 HDR Plasmid (bovine2) contain a puromycin resistance cassette and an RFP reporter flanked by homology arms to support homology-directed repair at defined target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.